未登录

J

Jayne Smith-Palmer

covalence research, harpenden, uk

H指数:19

被引数:1,465

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A systematic literature review and meta-analysis of real-world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes

对商业上可用的自动化胰岛素输送系统在1型糖尿病患者中的真实世界证据的系统文献综述与荟萃分析

Diabetes, Obesity and Metabolism

IF0

2025-10-080

OA

Automated Insulin Delivery Versus Standard of Care in the Management of People Living with Type 1 Diabetes and HbA1c <8%: A Cost-Utility Analysis in The Netherlands

DIABETES TECHNOLOGY & THERAPEUTICS

IF6.3

2025-03-010

PRE

A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes

DIABETES TECHNOLOGY & THERAPEUTICS

IF6.3

2023-12-017

PRE

Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

IF3.4

2021-01-056

OAAI

Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the UK

IF16.6

2020-07-0931

OAAI

Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey

DIABETES TECHNOLOGY & THERAPEUTICS

IF6.3

2019-12-0110

PREAI

Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes

最小670G混合闭环系统与持续皮下胰岛素输注治疗1型糖尿病的成本-效果分析

DIABETES TECHNOLOGY & THERAPEUTICS

IF6.3

2019-03-0141

PREAI

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

IF3.4

2019-02-118

OAAI

The nature and impact of stigma in patients with chronic hepatitis B: a systematic literature review

JOURNAL OF HEPATOLOGY

IF33

2018-04-011

PREAI

Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2017-06-0118

PREAI

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients

ADVANCES IN THERAPY

IF4

2016-02-2323

PREAI

Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France

DIABETES TECHNOLOGY & THERAPEUTICS

IF6.3

2016-02-0126

PREAI

SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITIES FOR ADULTS WITH TYPE 1 DIABETES

VALUE IN HEALTH

IF6

2015-11-010

OAAI

Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type1 diabetes: a systematic review

DIABETIC MEDICINE

IF3.4

2015-05-2860

PREAI

Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits

BMC INFECTIOUS DISEASES

IF3

2015-01-17148

OAAI

TRADITIONAL AND NON-TRADITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES: SYSTEMATIC REVIEW OF LONGITUDINAL STUDIES

VALUE IN HEALTH

IF6

2014-11-011

OAAI

Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2014-09-01173

PREAI

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

IF3.4

2013-01-0866

OAAI

A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin

ADVANCES IN THERAPY

IF4

2012-11-224

PRE

AN EVALUATION OF THE LONG-TERM COSTS AND EFFECTS OF A 1% REDUCTION IN HBA1C IN TYPE 2 DIABETES PATIENTS IN MALAYSIA

VALUE IN HEALTH

IF6

2012-11-010

OAAI